Insider Transactions in Q1 2021 at Meridian Bioscience Inc (VIVO)
Insider Transaction List (Q1 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 17
2021
|
John P. Kenny Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
30,000
-12.57%
|
$750,000
$25.0 P/Share
|
|
Mar 10
2021
|
John P. Kenny Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
10,000
-4.02%
|
$250,000
$25.0 P/Share
|
|
Feb 16
2021
|
John P. Kenny Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
2,359
-0.94%
|
$70,770
$30.35 P/Share
|
|
Feb 16
2021
|
John P. Kenny Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,082
+0.82%
|
$20,820
$10.1 P/Share
|
|
Feb 12
2021
|
John P. Kenny Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
26,181
-9.52%
|
$785,430
$30.14 P/Share
|
|
Feb 12
2021
|
John P. Kenny Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
23,097
+7.75%
|
$230,970
$10.1 P/Share
|
|
Feb 11
2021
|
John P. Kenny Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
1,320
-0.52%
|
$39,600
$30.0 P/Share
|
|
Feb 11
2021
|
John P. Kenny Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,164
+0.46%
|
$11,640
$10.1 P/Share
|
|
Feb 08
2021
|
John P. Kenny Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
68,288
-21.31%
|
$1,980,352
$29.86 P/Share
|
|
Feb 08
2021
|
John P. Kenny Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
66,134
+9.45%
|
$793,608
$12.3 P/Share
|
|
Feb 08
2021
|
Bryan T Baldasare Exec VP & CFO |
SELL
Open market or private sale
|
Direct |
6,254
-10.03%
|
$187,620
$30.0 P/Share
|
|
Feb 08
2021
|
Bryan T Baldasare Exec VP & CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
3,750
+5.67%
|
$71,250
$19.56 P/Share
|
|
Feb 08
2021
|
John Mc Cune Rice Jr. Director |
SELL
Open market or private sale
|
Direct |
16,480
-40.28%
|
$461,440
$28.16 P/Share
|
|
Feb 08
2021
|
John Mc Cune Rice Jr. Director |
BUY
Exercise of conversion of derivative security
|
Direct |
27,205
+29.63%
|
$326,460
$12.01 P/Share
|
|
Feb 05
2021
|
John P. Kenny Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
40,000
-7.04%
|
$1,000,000
$25.0 P/Share
|
|
Feb 05
2021
|
Bryan T Baldasare Exec VP & CFO |
SELL
Open market or private sale
|
Direct |
14,250
-19.55%
|
$370,500
$26.61 P/Share
|
|
Feb 05
2021
|
Bryan T Baldasare Exec VP & CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
11,250
+13.37%
|
$213,750
$19.56 P/Share
|
|
Jan 27
2021
|
James M. Anderson Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,545
+8.46%
|
-
|
|
Jan 27
2021
|
Anthony P Bihl Iii Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,545
+11.08%
|
-
|
|
Jan 27
2021
|
Dwight E Ellingwood Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,545
+9.76%
|
-
|
|
Jan 27
2021
|
John Mc Ilwraith Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,545
+7.63%
|
-
|
|
Jan 27
2021
|
David Phillips Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,545
+17.38%
|
-
|
|
Jan 27
2021
|
John Mc Cune Rice Jr. Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,545
+10.13%
|
-
|
|
Jan 27
2021
|
Catherine Sazdanoff Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,545
+10.33%
|
-
|
|
Jan 27
2021
|
Felicia Williams Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,545
+17.54%
|
-
|